An Antiviral Formulation with RNA Dependent RNA Polymerase & DNA Gyrase Suppressive Properties
The invention relates to a composition for antiviral use.
State of the Art
Antiviral agents are the pharmacological agents used against the virus infections. They are used in order to control or destroy the viral infection.
Currently existing antiviral therapies are the methods for temporarily suppressing the symptoms caused by the virus, rather than the virus itself, by way of suppression of the enzymes that regulate the capabilities of the viruses to self-replicate and to synthesize DNA from RNA. These components may not provide a permanent solution and they also become ineffective due to the tolerance developed by the virus to these agents in the medium term.
The invention no. EP19990203128 entitled “Antiviral compositions” relates to the pharmaceutical compositions of the antiviral compounds that may be administered to a mammal, particularly to a human with viral infection. These compositions include the particles, which may be obtained by melt-extruding a mixture containing one or more antiviral compound and one or more suitable water-soluble polymer and then milling said melt-extruded mixture.
As a result, the presence of the need for a composition for antiviral use and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.
Object of the Invention
In order to eliminate the disadvantages of the state of the art, an object of the invention is to cause permanent destruction in the structure and the function of the virus itself, owing to the tissue-selective increase in the production of nitric oxide (particularly in the tissues exposed to viral infection).
Another object of the invention is to effectively inhibit the DNA synthesis capability of the viruses and also the ability of the viruses to transfer the DNA they synthesize into the healthy cells that they have not yet invaded.
Another object of the invention is to support intracellular immunity by enhancing the TH1 immune reaction.
In order to achieve the aforesaid advantages, the invention is a composition for antiviral use, said composition being obtained by the components selected from the group comprising 1-protopanaxatriol, methylpanaxadiol, methylprotobioside that are used individually or in combinations.
Erdal Can Alkoclar is a Turkish Inventor, Scientist and Investor. Alkoclar is the co-founder and running president of Mas Pharmaceutials R&D company. He is the sole inventor of 143 applied and 282 pending patents; 44 of them being in current PCT protection. Alkoclar also is the rights holder and applicant of the largest amount of pharmaceutical ingredient patents as sole individual in Turkey. Alkoclar has won a 4th price which is given by Turkish Patent Institute for having the 4th largest number of applied patents in 2014 and The Scientist of the Year Awards for Turkey in 2016 and 2019. Alkoclar is nominated by DMW and EBCA as sole candidate for their Young Scientist of Europe Award of 2020